NYSE:MANE Veradermics (MANE) Stock Price, News & Analysis $128.16 -1.50 (-1.15%) As of 03:43 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Veradermics Stock (NYSE:MANE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Veradermics alerts:Sign Up Key Stats Today's Range$127.32▼$131.9450-Day Range$98.21▼$156.1152-Week Range$32.00▼$156.63Volume283,213 shsAverage Volume649,869 shsMarket Capitalization$5.41 billionP/E RatioN/ADividend YieldN/APrice Target$174.57Consensus RatingModerate Buy Company Overview Veradermics is a clinical-stage biopharmaceutical company focused on developing treatments for hair loss. Its lead candidate, VDPHL01, is an investigational oral formulation of minoxidil being studied for androgenetic alopecia, commonly known as male- or female-pattern hair loss. The company has described the treatment as designed for once-daily use. VDPHL01 remains under clinical investigation and is not an approved treatment. Veradermics is led by founder and Chief Executive Officer Reid Waldman, a physician specializing in dermatology.AI Generated. May Contain Errors. Read More Veradermics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreMANE MarketRank™: 3.06697612732 of 5 starsVeradermics scored higher than 61% of companies evaluated by MarketBeat, and ranked 352nd out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingVeradermics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialVeradermics has a consensus price target of $174.57, representing about 36.1% upside from its current price of $128.28.Amount of Analyst CoverageVeradermics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Veradermics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Veradermics are expected to decrease in the coming year, from ($2.87) to ($3.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Veradermics is -67.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Veradermics is -67.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.11% of the float of Veradermics has been sold short.Short Interest Ratio / Days to CoverVeradermics has a short interest ratio ("days to cover") of 5.06.Change versus previous monthShort interest in Veradermics has recently decreased by 8.36%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVeradermics does not currently pay a dividend.Dividend GrowthVeradermics does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.86 News SentimentVeradermics has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Veradermics this week, compared to 3 articles on an average week.Search InterestOnly 5 people have searched for MANE on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Veradermics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Veradermics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $167,598,220.00 in company stock.Percentage Held by InstitutionsVeradermics has minimal institutional ownership at this time.Read more about Veradermics' insider trading history. Receive MANE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Veradermics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MANE Stock News HeadlinesInsider Selling: Veradermics (NYSE:MANE) Major Shareholder Sells $75,190,000.00 in StockNovember 16 at 4:08 AM | americanbankingnews.comVeradermics (NYSE:MANE) Major Shareholder Sells $75,190,000.00 in StockNovember 15 at 12:52 PM | insidertrades.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 16 at 1:00 AM | Base Camp Trading (Ad)Veradermics, Incorporated (MANE) Discusses Positive Study 302 Part B Results for VDPHL01 in Pattern Hair Loss - SlideshowNovember 12, 2026 | seekingalpha.comVeradermics (NYSE:MANE) Stock Gets Price Target Boost from CitigroupNovember 12, 2026 | americanbankingnews.comVeradermics (NYSE:MANE) Sets New 52-Week High After Analyst UpgradeNovember 12, 2026 | americanbankingnews.comVeradermics: Q3 earnings snapshotNovember 10, 2026 | msn.comVeradermics (MANE) Stock Price Target 2026November 10, 2026 | benzinga.comSee More Headlines MANE Stock Analysis - Frequently Asked Questions How have MANE shares performed this year? Veradermics' stock was trading at $43.46 on February 16, 2026. Since then, MANE stock has increased by 195.2% and is now trading at $128.28. How were Veradermics' earnings last quarter? Veradermics, Incorporated (NYSE:MANE) announced its earnings results on Tuesday, November, 10th. The company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.59) by $0.09. When did Veradermics IPO? Veradermics (MANE) raised $226 million in an IPO on Wednesday, February 4th 2026. The company issued 15,077,647 shares at $14.00-$16.00 per share. Who are Veradermics' major shareholders? Top institutional investors of Veradermics include State Street Corp (1.52%), Marshall Wace LLP (0.44%), Alps Advisors Inc. (0.13%) and HighVista Strategies LLC (0.13%). Insiders that own company stock include Longitude Capital Partners V,, Montanova Capital, Llc, John W Childs, Reid Alexander Waldman and Timothy August Durso. View institutional ownership trends. How do I buy shares of Veradermics? Shares of MANE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/10/2026Today11/16/2026Jefferies Global Healthcare Conference11/19/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:MANE CIK1827635 Webwww.veradermics.com Phone(228) 372-3376FaxN/AEmployees21Year FoundedN/APrice Target and Rating Average Price Target for Veradermics$174.57 High Price Target$204.00 Low Price Target$135.00 Potential Upside/Downside+36.2%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$70 million Net MarginsN/A Pretax MarginN/A Return on Equity-20.50% Return on Assets-17.66% Debt Debt-to-Equity RatioN/A Current Ratio77.68 Quick Ratio77.68 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares42,195,000Free FloatN/AMarket Cap$5.41 billion OptionableOptionable BetaN/A Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NYSE:MANE) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredA Nasdaq drone company just landed a deal with a Philippine billionaire's groupA Nasdaq-listed drone company just signed an exclusive agreement with Prime Strategic Holdings, part of billio...The Tomorrow Investor | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredThe $40 trillion number nobody won on Tuesday will touchDemocrats took the House and Senate on election night, but the $40 trillion national debt and the $1 trillion ...Vault Metal | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veradermics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Veradermics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.